OnKure Therapeutics (NASDAQ:OKUR) Earns Sell (E+) Rating from Weiss Ratings

OnKure Therapeutics (NASDAQ:OKUR)‘s stock had its “sell (e+)” rating reissued by Weiss Ratings in a report released on Saturday,Weiss Ratings reports.

Several other equities analysts also recently weighed in on the stock. Zacks Research downgraded shares of OnKure Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 13th. HC Wainwright reaffirmed a “buy” rating and issued a $34.00 price objective on shares of OnKure Therapeutics in a report on Tuesday, August 26th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $32.33.

OnKure Therapeutics Stock Performance

OnKure Therapeutics stock opened at $3.32 on Friday. The stock has a 50-day moving average of $2.75 and a two-hundred day moving average of $2.56. OnKure Therapeutics has a one year low of $1.70 and a one year high of $17.93. The stock has a market cap of $44.92 million, a PE ratio of -0.69 and a beta of 0.43.

OnKure Therapeutics (NASDAQ:OKUR) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($1.14) EPS for the quarter, beating analysts’ consensus estimates of ($1.23) by $0.09. As a group, sell-side analysts predict that OnKure Therapeutics will post -4.05 EPS for the current fiscal year.

Institutional Investors Weigh In On OnKure Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Affinity Asset Advisors LLC increased its holdings in shares of OnKure Therapeutics by 173.4% during the 1st quarter. Affinity Asset Advisors LLC now owns 394,159 shares of the company’s stock valued at $1,695,000 after purchasing an additional 250,000 shares in the last quarter. ADAR1 Capital Management LLC acquired a new stake in OnKure Therapeutics during the first quarter valued at $43,000. Bailard Inc. purchased a new position in OnKure Therapeutics in the second quarter valued at $34,000. Highbridge Capital Management LLC raised its position in shares of OnKure Therapeutics by 51.2% in the second quarter. Highbridge Capital Management LLC now owns 663,607 shares of the company’s stock worth $1,586,000 after acquiring an additional 224,810 shares during the period. Finally, XTX Topco Ltd purchased a new stake in shares of OnKure Therapeutics during the 2nd quarter worth about $25,000. Hedge funds and other institutional investors own 90.98% of the company’s stock.

OnKure Therapeutics Company Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.